Finance

Lists
Why is IBRX down 6.65%?
Dive Deeper
IBRX:NASDAQ
Immunitybio Inc
$9.69
-6.65%
(-0.69) 1D
$9.73
+0.40% (+0.039)
Pre-market
Closed: Oct 6, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IBRX...
Open
$10.32
High
$10.36
Low
$9.61
Mkt. cap
10.18B
Avg. vol.
11.64M
Volume
5.28K
52-wk high
$12.43
52-wk low
$1.95
EPS
-$0.97
Beta
0.02
Shares outstanding
1.06B
No. of employees
688
Open
$10.32
High
$10.36
Low
$9.61
Mkt. cap
10.18B
Avg. vol.
11.64M
Volume
5.28K
52-wk high
$12.43
52-wk low
$1.95
EPS
-$0.97
Beta
0.02
Shares outstanding
1.06B
No. of employees
688
News stories
From web sources and news partners
About Immunitybio Inc
CEORich Adcock
Employees688
Founded2014
Headquarters-
SectorBiotechnology
Websiteimmunitybio.com
Analyst ratings
Based on 3 analysts giving stock ratings to IBRX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for IBRX in the last 3 months.
Highest
Current $9.69
$15.00 (+54.80%)
Average
$13.00 (+34.16%)
Lowest
$12.00 (+23.84%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Tenthoff
Piper Sandler
Buy
Reiterated
$12.00
+23.8%
09/08/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$12.00
+23.8%
08/04/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$15.00
+54.8%
08/04/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.22 / -$0.08
-175.00%miss
Revenue / Est. (USD)
51.24M / 49.70M
+3.10%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
32.06M
38.28M
44.21M
51.24M
Cost of goods sold
177.00K
382.00K
238.00K
298.00K
Cost of revenue
177.00K
382.00K
238.00K
298.00K
Research and development expenses
50.13M
67.26M
67.99M
60.82M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
37.38M
35.33M
45.77M
51.82M
Operating expense
87.51M
102.59M
113.76M
112.64M
Total operating expenses
87.69M
102.97M
114.00M
112.94M
Operating income
-55.63M
-64.68M
-69.79M
-61.70M
Other non operating income
13.84M
27.48M
-529.45M
-140.60M
EBT including unusual items
-67.31M
-62.09M
-632.79M
-230.39M
EBT excluding unusual items
-67.31M
-62.09M
-625.39M
-230.39M
Income tax expense
-35.00K
-135.00K
9.00K
-
Effective tax rate
0.05%
0.22%
-
-
Other operating expenses
-
-
-
-
Net income
-67.25M
-61.94M
-632.78M
-230.38M
Net profit margin
-209.77%
-161.80%
-1,431.44%
-449.61%
Earnings per share
-0.07
-0.06
-0.08
-0.22
Interest and investment income
2.07M
2.30M
2.31M
3.16M
Interest expense
-27.58M
-27.19M
-28.46M
-31.24M
Net interest expenses
-25.52M
-24.89M
-26.15M
-28.09M
Depreciation and amortization charges
-
-
-
-
EBITDA
-51.68M
-60.92M
-65.41M
-57.29M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps